Gilead Sciences (GILD): Cutting Numbers Slightly on Slower Switching - Leerink
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but cut the price target to $112.00 from $114.00. The analyst underestimated the company’s US volume growth but also overestimated the rate of switching from legacy products onto new TAF-based regimens. As a result of the updates, the analyst now forecasts a slightly lower Revenue/TRx trend due to slower-than-expected switching to TAF based regimens from legacy combinations.
The analyst is expecting Gilead’s HIV products to generate WW sales of $20.5bn in 2021E vs. the previous forecast of $22.6bn.
Shares of Gilead Sciences closed at $81.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Susquehanna Cuts Price Target on KLA-Tencor (KLAC) Following Strong 1Q
- FBR & Co. Sees Quick Resolution to Aduro Biotech's (ADRO) Partial Clinical Hold; Trims PT to $20
- UPDATE: Seaport Global Securities Starts Canadian Pacific Railway Limited (CP) at Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!